These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28197733)

  • 1. Relationship between exercise capacity and urinary liver-type fatty acid-binding protein in middle-aged and older individuals.
    Kosaki K; Kamijo-Ikemori A; Sugaya T; Tanahashi K; Kumagai H; Sawano Y; Akazawa N; Ra SG; Kimura K; Shibagaki Y; Maeda S
    Clin Exp Nephrol; 2017 Oct; 21(5):810-817. PubMed ID: 28197733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of habitual exercise on urinary liver-type fatty acid-binding protein levels in middle-aged and older adults.
    Kosaki K; Kamijo-Ikemori A; Sugaya T; Tanahashi K; Sawano Y; Akazawa N; Ra SG; Kimura K; Shibagaki Y; Maeda S
    Scand J Med Sci Sports; 2018 Jan; 28(1):152-160. PubMed ID: 28247579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NGAL, L-FABP, and KIM-1 in comparison to established markers of renal dysfunction.
    Holzscheiter L; Beck C; Rutz S; Manuilova E; Domke I; Guder WG; Hofmann W
    Clin Chem Lab Med; 2014 Apr; 52(4):537-46. PubMed ID: 24243749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary excretion of fatty acid-binding protein 4 is associated with albuminuria and renal dysfunction.
    Okazaki Y; Furuhashi M; Tanaka M; Mita T; Fuseya T; Ishimura S; Watanabe Y; Hoshina K; Akasaka H; Ohnishi H; Yoshida H; Saitoh S; Shimamoto K; Miura T
    PLoS One; 2014; 9(12):e115429. PubMed ID: 25506691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary human L-FABP is a potential biomarker to predict COX-inhibitor-induced renal injury.
    Tanaka T; Noiri E; Yamamoto T; Sugaya T; Negishi K; Maeda R; Nakamura K; Portilla D; Goto M; Fujita T
    Nephron Exp Nephrol; 2008; 108(1):e19-26. PubMed ID: 18182783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [L-type fatty acid binding protein (L-FABP) and kidney disease].
    Kamijo-Ikemori A; Sugaya T; Kimura K
    Rinsho Byori; 2014 Feb; 62(2):163-70. PubMed ID: 24800492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver fatty-acid-binding protein in heart and kidney allograft recipients in relation to kidney function.
    Przybylowski P; Koc-Zorawska E; Malyszko JS; Kozlowska S; Mysliwiec M; Malyszko J
    Transplant Proc; 2011 Oct; 43(8):3064-7. PubMed ID: 21996226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease.
    Yang X; Zhang B; Lu X; Yan M; Wen Y; Zhao T; Li P
    BMC Complement Altern Med; 2016 Jul; 16():246. PubMed ID: 27460780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial.
    Kamijo A; Sugaya T; Hikawa A; Yamanouchi M; Hirata Y; Ishimitsu T; Numabe A; Takagi M; Hayakawa H; Tabei F; Sugimoto T; Mise N; Kimura K
    J Lab Clin Med; 2005 Mar; 145(3):125-33. PubMed ID: 15871303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of renal function on serum and urinary heart fatty acid-binding protein levels.
    Nayashida N; Chihara S; Tayama E; Akasu K; Kai E; Kawara T; Aoyagi S
    J Cardiovasc Surg (Torino); 2001 Dec; 42(6):735-40. PubMed ID: 11698938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal expression and urinary excretion of liver-type fatty acid-binding protein in cats with renal disease.
    Katayama M; Ohata K; Miyazaki T; Katayama R; Wakamatsu N; Ohno M; Yamashita T; Oikawa T; Sugaya T; Miyazaki M
    J Vet Intern Med; 2020 Mar; 34(2):761-769. PubMed ID: 32087614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of urinary liver-type fatty acid-binding protein with cardiovascular risk factors in the Japanese population without chronic kidney disease: Sasayama study.
    Kubota Y; Higashiyama A; Marumo M; Konishi M; Yamashita Y; Okamura T; Miyamoto Y; Wakabayashi I
    BMC Nephrol; 2021 May; 22(1):189. PubMed ID: 34020611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary Liver Type Fatty Acid Binding Protein Is Negatively Associated With Estimated Glomerular Filtration Rate in Renal Transplant Recipients With Graft Loss.
    Huang YC; Chang YS; Chen CC; Tsai SF; Yu TM; Wu MJ; Chen CH
    Transplant Proc; 2018 May; 50(4):1083-1086. PubMed ID: 29731071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between Urinary Liver-Type Fatty Acid-Binding Protein (L-FABP) and Sarcopenia in Spontaneously Diabetic Torii Fatty Rats.
    Tanabe J; Ogura Y; Kosaki K; Nagai Y; Sugaya T; Ohata K; Watanabe S; Ichikawa D; Inoue K; Hoshino S; Kimura K; Maeda S; Shibagaki Y; Kamijo-Ikemori A
    J Diabetes Res; 2020; 2020():7614035. PubMed ID: 32405506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.
    Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Inoue T; Node K
    Am J Nephrol; 2006; 26(1):82-6. PubMed ID: 16534182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease.
    Kamijo A; Sugaya T; Hikawa A; Yamanouchi M; Hirata Y; Ishimitsu T; Numabe A; Takagi M; Hayakawa H; Tabei F; Sugimoto T; Mise N; Omata M; Kimura K
    Mol Cell Biochem; 2006 Mar; 284(1-2):175-82. PubMed ID: 16532260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary liver-type fatty acid-binding protein is associated with subendocardial viability ratio in middle- and older-aged adults.
    Kosaki K; Kamijo-Ikemori A; Sugaya T; Tanahashi K; Kumagai H; Sawano Y; Akazawa N; Osuka Y; Tanaka K; Kimura K; Shibagaki Y; Maeda S
    Clin Exp Hypertens; 2018; 40(3):244-250. PubMed ID: 28872349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of urinary liver-type fatty acid binding protein measured by latex-enhanced turbidimetric immunoassay in chronic kidney disease.
    Kamijo-Ikemori A; Sugaya T; Yoshida M; Hoshino S; Akatsu S; Yamazaki S; Kimura K; Shibagaki Y
    Clin Chem Lab Med; 2016 Oct; 54(10):1645-54. PubMed ID: 26943609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of a urinary biomarker panel for obstructive nephropathy and clinical outcomes.
    Xie Y; Xue W; Shao X; Che X; Xu W; Ni Z; Mou S
    PLoS One; 2014; 9(11):e112865. PubMed ID: 25402279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis.
    Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
    Clin Nephrol; 2006 Jan; 65(1):1-6. PubMed ID: 16429835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.